You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2025

Bulk Pharmaceutical API Sources for ZEGERID


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ZEGERID

Vendor Vendor Homepage Vendor Sku API Url
ChemExper Chemical Directory ⤷  Get Started Free jakqb@BTeCIPAFRSQIJIIQIHiK`gICEij`@HBj`@@@ ⤷  Get Started Free
Sigma-Aldrich ⤷  Get Started Free O104_SIGMA ⤷  Get Started Free
Calbiochem ⤷  Get Started Free 496100 ⤷  Get Started Free
NIH Clinical Collection ⤷  Get Started Free SAM001246900 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for ZEGERID

Last updated: August 1, 2025

Introduction

ZEGERID (omeprazole and magnesium hydroxide) is a combination drug primarily utilized for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. As an innovator or generic pharmaceutical manufacturer, sourcing high-quality Active Pharmaceutical Ingredients (APIs) is crucial to ensure drug efficacy, safety, regulatory compliance, and cost management. This article explores the various sources for bulk APIs used in ZEGERID, with a focus on omeprazole and magnesium hydroxide, emphasizing their supply chain dynamics, quality standards, and market considerations.


Overview of API Components in ZEGERID

Omeprazole: A proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly blocking the H+/K+ ATPase enzyme system. It’s chemically synthesized and requires stringent quality controls due to its complexity and sensitivity to degradation.

Magnesium Hydroxide: An inorganic antacid that neutralizes stomach acid. Its sourcing involves mineral extraction and purification processes, often with rigorous quality parameters to prevent impurities and ensure stability.


Sourcing of Omeprazole API

1. Leading Global Manufacturers

Omeprazole APIs are produced by several established multinational pharmaceutical ingredient manufacturers. The top players include:

  • Hetero Labs (India): Known for large-scale production and cost competitiveness, Hetero supplies high-purity omeprazole APIs certified to international standards (e.g., USP, EP, BP). Their facilities are inspected by global regulators, including the US FDA and EMA.

  • API International: Offers compliant APIs with a focus on North American and European markets, providing a reliable supply chain for generic manufacturers.

  • Xiamen Innovax Biotech & Zhejiang Huahai Pharmaceuticals (China): These firms are prominent Chinese API producers with extensive production capacities. They hold certifications such as GMP, and some have achieved U.S. FDA approval statuses for their APIs.

  • Dr. Reddy’s Laboratories (India): A reputable supplier known for high-quality APIs that meet global pharmaceutical standards, serving both proprietary and generic formulations.

2. Quality and Certification Standards

API sourcing must align with regulatory standards:

  • GMP Certification: Ensures consistent quality and safety, especially for APIs intended for export to developed markets.

  • Regulatory Approvals: Suppliers with U.S. FDA, EMA, or PMDA approvals often facilitate faster registration and compliance for ZEGERID formulations.

  • Certifications: Certificates of Analysis (COA), Material Safety Data Sheets (MSDS), and stability data are requisites for validating API quality.

3. Supply Chain Dynamics and Challenges

  • Consolidation & Capacity: The global API market has seen consolidation, which influences supplier stability and pricing.

  • Price Fluctuations: Currency, raw material costs, and regulatory compliance costs impact API pricing, influencing the overall manufacturing cost of ZEGERID.

  • Vietnam & Indian Market: Increasing production capacities in these regions offer reduced costs but sometimes pose regulatory considerations.

4. Alternatives & Generic API Suppliers

  • Sino-American Pharmaceutical Enterprises: Emerging players offering cost-effective APIs, but with variable regulatory acceptance.

  • Contract Manufacturing Organizations (CMOs): Offer customized API manufacturing with assured quality, often providing supply chain flexibility.


Sourcing of Magnesium Hydroxide API

1. Natural Mineral Sources and Purification

Magnesium hydroxide is primarily derived from naturally occurring mineral sources such as magnesite and brucite. The key considerations include:

  • Mining & Extraction: Leading companies like Naoussa Magnesite Mine (Greece) and Lunzhou Group (China) extract mineral sources, followed by chemical purification.

  • Purity & Quality Standards: Pharmaceutical-grade magnesium hydroxide must meet USP or Ph. Eur. specifications, emphasizing low insoluble impurities, heavy metals, and microbial contamination.

2. Manufacturers & Key Players

  • Shandong Grand Fertilizer Co., Ltd. (China): Produces pharmaceutical-grade magnesium hydroxide with GMP compliance.

  • Hubei Jusheng Technology Co., Ltd. (China): Supplies high-purity magnesium hydroxide API, suitable for antacid formulations like ZEGERID.

  • Evonik Industries (Germany): Offers specialty grades of magnesium hydroxide for pharmaceutical applications, emphasizing advanced purification techniques.

  • Taiwanese & European Suppliers: Known for consistent quality and reliable supply, often preferred by global manufacturers.

3. Supply Chain Considerations

  • Raw Material Availability: Mineral supply can be affected by geopolitical or environmental factors, influencing prices and availability.

  • Certification and Compliance: Suppliers with validated GMP processes, comprehensive COAs, and compliance attestations streamline regulatory approval processes.

  • Environmental & Ethical Sourcing: Increasing emphasis on sustainable mining practices impacts supplier selection.


Market Dynamics in API Sourcing for ZEGERID

1. Regulatory Landscape

Global regulatory environments significantly influence API sourcing:

  • Stringent Quality Control: Regulatory agencies impose strict testing standards, periodic audits, and certification requirements.

  • Supply Chain Transparency: Traceability of raw materials and manufacturing processes is mandatory.

  • Local vs. International Suppliers: While local suppliers can reduce logistics costs, international GMP-certified suppliers often provide easier regulatory acceptance.

2. Cost Considerations

Pricing varies based on supplier location, scale, compliance, and associated logistics. Indian and Chinese suppliers generally offer lower costs but require rigorous validation and regulatory oversight for international markets.

3. Strategic Sourcing Approaches

  • Dual Sourcing: To avoid shortages and mitigate risks, companies often establish relationships with multiple suppliers.

  • Long-term Agreements: Contracts with key suppliers ensure price stability and reliability.

  • Technology Transfer & Quality Agreements: Facilitates consistent API quality across manufacturing sites.


Conclusion

Sourcing high-quality APIs for ZEGERID requires careful selection of suppliers, considering quality standards, regulatory approvals, supply chain stability, and cost efficiency. For omeprazole, leading manufacturers in India, China, and Europe who meet international GMP standards are preferred. The magnesium hydroxide component relies on mineral sources and chemical purification, with reputable suppliers from Asia and Europe ensuring compliance. Strategic partnerships, robust quality assurance, and regulatory alignment are essential to maintaining supply continuity and safeguarding product integrity.


Key Takeaways

  • Regulatory compliance is non-negotiable; choose suppliers with GMP certifications and regulatory approvals (FDA, EMA, etc.).
  • Quality assurance involves ongoing audits, COA reviews, and validation to mitigate risks associated with impurities and batch variability.
  • Supply diversification reduces dependency on single sources, ensuring uninterrupted API availability.
  • Cost considerations must be balanced with quality and compliance, especially when sourcing from low-cost regions.
  • Market intelligence—tracking geopolitical, environmental, and market trends—enhances procurement strategies for APIs used in ZEGERID.

FAQs

1. What are the primary challenges in sourcing APIs for ZEGERID?
Ensuring consistent quality, compliance with regulatory standards, managing supply chain disruptions, and balancing costs are key challenges.

2. How do regulatory certifications influence API sourcing decisions?
Certifications like GMP, FDA approval, and international standards streamline approval processes, reduce compliance risks, and assure quality.

3. Are there risks associated with sourcing APIs from emerging markets like China or India?
While cost advantages are significant, risks include variability in quality, regulatory acceptance, and supply chain stability, necessitating rigorous qualification processes.

4. Can synthetic routes impact API quality or sourcing?
Yes. Synthetic pathways can influence purity, yield, and impurity profiles. Suppliers with validated, scalable synthetic methods usually provide higher reliability.

5. How is the sustainability of mineral-based magnesium hydroxide affects sourcing?
Sustainable and ethically sourced minerals influence supplier selection, meeting environmental regulations, and corporate responsibility standards.


References

  1. U.S. Pharmacopeia (USP). Omeprazole Monograph.
  2. European Pharmacopoeia (EP). Magnesium Hydroxide Monograph.
  3. GlobalData. Pharmaceutical Active Ingredient Market Insights.
  4. Indian Pharmacopoeia Commission. Guidelines on API quality standards.
  5. Regulatory dossier submitted by leading API manufacturers to regulators, 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.